Describe the Role of Trelegy and Triple Therapy for Asthma

The "three-in-one" Trelegy Ellipta inhaler is now approved for ASTHMA...not just for COPD.

Trelegy contains the inhaled corticosteroid (ICS) fluticasone furoate...the long-acting beta-agonist (LABA) vilanterol...and the long-acting muscarinic antagonist (LAMA) umeclidinium.

Trelegy seems to improve lung function in asthma patients not controlled on a medium- or high-dose ICS/LABA...but isn't yet shown to reduce exacerbations.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals